Inhibition of collar-induced carotid atherosclerosis by recombinant apoA-I cysteine mutants in apoE-deficient mice

Journal of Lipid Research

Volumn 51, Issue 12, 2010, Pages 3434-3442

  Zhang, Xinbo ^a   Zhu, Xuewei ^b   Chen, Baosheng ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Antioxidant; Apolipoprotein; Cytokines

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN A1(N74C); CYSTEINE; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; MUTANT PROTEIN; RECOMBINANT HDL 74; RECOMBINANT HDLMILANO; RECOMBINANT HDLWT; RECOMBINANT HIGH DENSITY LIPOPROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; AORTA INTIMA; AORTA MEDIA; ARTICLE; ATHEROSCLEROTIC PLAQUE; CAROTID ATHEROSCLEROSIS; CONTROLLED STUDY; DEVICE; HEART PROTECTION; HYPERLIPOPROTEINEMIA TYPE 3; IN VITRO STUDY; IN VIVO STUDY; LIPID STORAGE; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIOXIDANTS; APOLIPOPROTEIN A-I; APOLIPOPROTEINS E; CAROTID ARTERY DISEASES; CYTOKINES; INJECTIONS, INTRAVENOUS; INTERLEUKIN-6; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MUTATION; OXIDATION-REDUCTION; RECOMBINANT PROTEINS;

EID: 78650049576     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M008573     Document Type: Article

References (44)

1. Gordon, T., W. P. Castelli, M. C. Hjortland, W. B. Kannel, and T. R. Dawber. 1977. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am. J. Med. 62: 707-714.
2. Miller, N. E., D. S. Thelle, O. H. Forde, and O. D. Mjos. 1977. The Tromso heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study. Lancet. 1: 965-968.
3. Tall, A. R. 1990. Plasma high density lipoproteins. Metabolism and relationship to atherogenesis. J. Clin. Invest. 86: 379-384.
4. Boisvert, W. A., A. S. Black, and L. K. Curtiss. 1999. ApoA1 reduces free cholesterol accumulation in atherosclerotic lesions of ApoE-deficient mice transplanted with ApoE-expressing macrophages. Arterioscler. Thromb. Vasc. Biol. 19: 525-530.
5. Pajkrt, D., J. E. Doran, F. Koster, P. G. Lerch, B. Arnet, T. van der Poll, J. W. ten Cate, and S. J. van Deventer. 1996. Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J. Exp. Med. 184: 1601-1608.
6. Barter, P. J., S. Nicholls, K. A. Rye, G. M. Anantharamaiah, M. Navab, and A. M. Fogelman. 2004. Antiinflammatory properties of HDL. Circ. Res. 95: 764-772.
7. Parker, T. S., D. M. Levine, J. C. Chang, J. Laxer, C. C. Coffin, and A. L. Rubin. 1995. Reconstituted high-density lipoprotein neutralizes gram-negative bacterial lipopolysaccharides in human whole blood. Infect. Immun. 63: 253-258.
8. Nicholls, S. J., G. J. Dusting, B. Cutri, S. Bao, G. R. Drummond, K. A. Rye, and P. J. Barter. 2005. Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation. 111: 1543-1550.
9. Weisgraber, K. H., S. C. Rall, Jr., T. P. Bersot, R. W. Mahley, G. Franceschini, and C. R. Sirtori. 1983. Apolipoprotein A-IMilano. Detection of normal A-I in affected subjects and evidence for a cysteine for arginine substitution in the variant A-I. J. Biol. Chem. 258: 2508-2513.
10. Sirtori, C. R., L. Calabresi, G. Franceschini, D. Baldassarre, M. Amato, J. Johansson, M. Salvetti, C. Monteduro, R. Zulli, M. L. Muiesan, et al. 2001. Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the Limone sul Garda study. Circulation. 103: 1949-1954.
11. Bruckert, E., A. von Eckardstein, H. Funke, I. Beucler, H. Wiebusch, G. Turpin, and G. Assmann. 1997. The replacement of arginine by cysteine at residue 151 in apolipoprotein A-I produces a phenotype similar to that of apolipoprotein A-IMilano. Atherosclerosis. 128: 121-128. (Pubitemid 27065268)
12. Shah, P. K., J. Nilsson, S. Kaul, M. C. Fishbein, H. Ageland, A. Hamsten, J. Johansson, F. Karpe, and B. Cercek. 1998. Effects of recombinant apolipoprotein A-I(Milano) on aortic atherosclerosis in apolipoprotein E-deficient mice. Circulation. 97: 780-785.
13. Li, D., S. Weng, B. Yang, D. S. Zander, T. Saldeen, W. W. Nichols, S. Khan, and J. L. Mehta. 1999. Inhibition of arterial thrombus formation by ApoA1 Milano. Arterioscler. Thromb. Vasc. Biol. 19: 378-383.
14. Kaul, S., V. Rukshin, R. Santos, B. Azarbal, C. L. Bisgaier, J. Johansson, V. T. Tsang, K. Y. Chyu, B. Cercek, J. Mirocha, et al. 2003. Intramural delivery of recombinant apolipoprotein A-IMilano/phospholipid complex (ETC-216) inhibits in-stent stenosis in porcine coronary arteries. Circulation. 107: 2551-2554.
15. Nissen, S. E., T. Tsunoda, E. M. Tuzcu, P. Schoenhagen, C. J. Cooper, M. Yasin, G. M. Eaton, M. A. Lauer, W. S. Sheldon, C. L. Grines, et al. 2003. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 290: 2292-2300.
16. Nicholls, S. J., E. M. Tuzcu, I. Sipahi, P. Schoenhagen, T. Crowe, S. Kapadia, and S. E. Nissen. 2006. Relationship between atheroma regression and change in lumen size after infusion of apolipoprotein A-I Milano. J. Am. Coll. Cardiol. 47: 992-997.
17. Shah, P. K., J. Yano, O. Reyes, K. Y. Chyu, S. Kaul, C. L. Bisgaier, S. Drake, and B. Cercek. 2001. High-dose recombinant apolipoprotein A-I(milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein e-deficient mice. Potential implications for acute plaque stabilization. Circulation. 103: 3047-3050.
18. Segrest, J. P., D. W. Garber, C. G. Brouillette, S. C. Harvey, and G. M. Anantharamaiah. 1994. The amphipathic alpha helix: a multi-functional structural motif in plasma apolipoproteins. Adv. Protein Chem. 45: 303-369.
19. Zhu, X., G. Wu, W. Zeng, H. Xue, and B. Chen. 2005. Cysteine mutants of human apolipoprotein A-I: a study of secondary structural and functional properties. J. Lipid Res. 46: 1303-1311. (Pubitemid 43109845)
20. Wang, Y., X. Zhu, G. Wu, L. Shen, and B. Chen. 2008. Effect of lipid-bound apoA-I cysteine mutants on lipopolysaccharide-induced endotoxemia in mice. J. Lipid Res. 49: 1640-1645.
21. von der Thusen, J. H., T. J. van Berkel, and E. A. Biessen. 2001. Induction of rapid atherogenesis by perivascular carotid collar placement in apolipoprotein E-deficient and low-density lipoprotein receptor-deficient mice. Circulation. 103: 1164-1170.
22. Baetta, R., F. Silva, C. Comparato, M. Uzzo, I. Eberini, S. Bellosta, E. Donetti, and A. Corsini. 2007. Perivascular carotid collar placement induces neointima formation and outward arterial remodeling in mice independent of apolipoprotein E deficiency or Western-type diet feeding. Atherosclerosis. 195: e112-e124.
23. Chen, C. H., and J. J. Albers. 1982. Characterization of proteoliposomes containing apoprotein A-I: a new substrate for the measurement of lecithin:cholesterol acyltransferase activity. J. Lipid Res. 23: 680-691.
24. Koizumi, J., M. Kano, K. Okabayashi, A. Jadhav, and G. R. Thompson. 1988. Behavior of human apolipoprotein A-I: phospholipid and apoHDL:phospholipid complexes in vitro and after injection into rabbits. J. Lipid Res. 29: 1405-1415.
25. Draper, H. H., and M. Hadley. 1990. Malondialdehyde determination as index of lipid peroxidation. Methods Enzymol. 186: 421-431.
26. Cho, K. H. 2009. Synthesis of reconstituted high density lipoprotein (rHDL) containing apoA-I and apoC-III: the functional role of apoC-III in rHDL. Mol. Cells. 27: 291-297.
27. Guo, G. L., S. Santamarina-Fojo, T. E. Akiyama, M. J. Amar, B. J. Paigen, B. Brewer, Jr., and F. J. Gonzalez. 2006. Effects of FXR in foam-cell formation and atherosclerosis development. Biochim. Biophys. Acta. 1761: 1401-1409.
28. Benzie, I. F., and J. J. Strain. 1996. The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": the FRAP assay. Anal. Biochem. 239: 70-76.
29. Aviram, M., S. Billecke, R. Sorenson, C. Bisgaier, R. Newton, M. Rosenblat, J. Erogul, C. Hsu, C. Dunlop, and B. La Du. 1998. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler. Thromb. Vasc. Biol. 18: 1617-1624.
30. Johnson, J., K. Carson, H. Williams, S. Karanam, A. Newby, G. Angelini, S. George, and C. Jackson. 2005. Plaque rupture after short periods of fat feeding in the apolipoprotein E-knockout mouse: model characterization and effects of pravastatin treatment. Circulation. 111: 1422-1430.
31. Naghavi, M., P. Wyde, S. Litoversusky, M. Madjid, A. Akhtar, S. Naguib, M. S. Siadaty, S. Sanati, and W. Casscells. 2003. Influenza infection exerts prominent inflammatory and thrombotic effects on the atherosclerotic plaques of apolipoprotein E-deficient mice. Circulation. 107: 762-768.
32. Cho, K. H., S. H. Park, J. M. Han, H. C. Kim, Y. K. Choi, and I. Choi. 2006. ApoA-I mutants V156K and R173C promote anti-inflammatory function and antioxidant activities. Eur. J. Clin. Invest. 36: 875-882.
33. Cho, K. H. 2009. A reconstituted high density lipoprotein containing the V156E mutant of apolipoprotein A-I exhibits anti-atherosclerotic activity in Apo-E deficient mice. J. Atheroscler. Thromb. 16: 217-229.
34. Cho, K. H., and J. R. Kim. 2009. A reconstituted HDL containing V156K or R173C apoA-I exhibited anti-inflammatory activity in apo-E deficient mice and showed resistance to myeloperoxidase-mediated oxidation. Exp. Mol. Med. 41: 417-428.
35. Baker, P. W., K. A. Rye, J. R. Gamble, M. A. Vadas, and P. J. Barter. 1999. Ability of reconstituted high density lipoproteins to inhibit cytokine-induced expression of vascular cell adhesion molecule-1 in human umbilical vein endothelial cells. J. Lipid Res. 40: 345-353.
36. Cockerill, G. W., T. Y. Huehns, A. Weerasinghe, C. Stocker, P. G. Lerch, N. E. Miller, and D. O. Haskard. 2001. Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation. Circulation. 103: 108-112.
37. Pasterkamp, G., Z. S. Galis, and D. P. de Kleijn. 2004. Expansive arterial remodeling: location, location, location. Arterioscler. Thromb. Vasc. Biol. 24: 650-657.
38. Woollard, K. J., and F. Geissmann. Monocytes in atherosclerosis: subsets and functions. Nat. Rev. Cardiol. 7: 77-86.
39. Toshima, S., A. Hasegawa, M. Kurabayashi, H. Itabe, T. Takano, J. Sugano, K. Shimamura, J. Kimura, I. Michishita, T. Suzuki, et al. 2000. Circulating oxidized low density lipoprotein levels. A biochemical risk marker for coronary heart disease. Arterioscler. Thromb. Vasc. Biol. 20: 2243-2247.
40. Oda, M. N., J. K. Bielicki, T. Berger, and T. M. Forte. 2001. Cysteine substitutions in apolipoprotein A-I primary structure modulate paraoxonase activity. Biochemistry. 40: 1710-1718.
41. Ross, R. 1999. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 340: 115-126.
42. Tzoulaki, I., G. D. Murray, A. J. Lee, A. Rumley, G. D. Lowe, and F. G. Fowkes. 2005. C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh Artery Study. Circulation. 112: 976-983.
43. Schieffer, B., T. Selle, A. Hilfiker, D. Hilfiker-Kleiner, K. Grote, U. J. Tietge, C. Trautwein, M. Luchtefeld, C. Schmittkamp, S. Heeneman, et al. 2004. Impact of interleukin-6 on plaque development and morphology in experimental atherosclerosis. Circulation. 110: 3493-3500. (Pubitemid 39602229)
44. Huber, S. A., P. Sakkinen, D. Conze, N. Hardin, and R. Tracy. 1999. Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscler. Thromb. Vasc. Biol. 19: 2364-2367